Omnicell (OMCL) to Release Earnings on Thursday

Omnicell (NASDAQ:OMCL) will likely be announcing its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.57 per share and revenue of $297.88 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Omnicell Stock Performance

OMCL opened at $43.85 on Wednesday. The company has a market cap of $2.03 billion, a PE ratio of -112.43, a price-to-earnings-growth ratio of 30.78 and a beta of 0.78. The stock has a 50-day moving average of $44.64 and a 200-day moving average of $43.10. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on OMCL shares. Barclays increased their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday. Bank of America decreased their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Craig Hallum lifted their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $52.33.

Insider Activity

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.64% of the stock is owned by company insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.